Eliadou Elena, Day Andrew S, Thompson-Fawcett Mark W, Gearry Richard B, Rowbotham David S, Walmsley Russel, Schultz Michael, Inns Stephen J
Hutt Valley DHB IBD Service, Private Bag 31907, Lower Hutt 5040 and Department of Medicine, University of Otago, Wellington, on behalf of IBDNZ.
N Z Med J. 2015 Oct 16;128(1423):63-76.
The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging. The development of newer medical therapies has increased the options for managing patients in this situation, but access and funding remain limited. This guideline summarises the literature regarding this situation and provides guidance as to the management of refractory colitis in the New Zealand setting.
对于依赖皮质类固醇来控制症状、或对皮质类固醇或标准免疫抑制疗法无效的溃疡性结肠炎患者,其管理颇具挑战性。新型药物疗法的出现增加了管理此类患者的选择,但获取途径和资金仍然有限。本指南总结了关于这种情况的文献,并针对新西兰环境下难治性结肠炎的管理提供指导。